• Publications
  • Influence
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
TLDR
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes. Expand
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
TLDR
Whether captopril has kidney-protecting properties independent of its effect on blood pressure in diabetic nephropathy is determined. Expand
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
TLDR
Aliskiren may have renoprotective effects that are independent of its blood-pressure-lowering effect in patients with hypertension, type 2 diabetes, and nephropathy who are receiving the recommended renoprotsective treatment. Expand
Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy
TLDR
The analysis of the cardiovascular end points that were monitored as secondary end points in the Irbesartan Diabetic Nephropathy Trial (IDNT) was reported to assess whether an angiotensin II receptor blocker or a calcium-channel blocker alters the risk for cardiovascular events beyond those observed by blood pressure reduction alone without such agents. Expand
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
TLDR
A SBP target between 120 and 130 mmHg is recommended, in conjunction with blockade of the renin-angiotensin system, in patients with type 2 diabetic nephropathy, and Progressive lowering of SBP to 120mmHg was associated with improved renal and patient survival, an effect independent of baseline renal function. Expand
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
TLDR
Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone. Expand
Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants.
TLDR
Because the remission rate after treatment is similar among patients with the histologic variants, response to therapy cannot be predicted on the basis of histology alone and nephrotic patients with primary FSGS should receive a trial of therapy irrespective of thehistologic lesion when not contraindicated. Expand
GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
TLDR
A scientific workshop to critically examine available data to determine whether alternative GFR-based end points have sufficiently strong relationships with important clinical outcomes of CKD to be used in clinical trials concluded that a confirmed decline in estimated GFR of 30% over 2 to 3 years may be an acceptable surrogate end point in some circumstances. Expand
Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs.
TLDR
The case of a woman with a history of pulmonary-renal syndrome caused by MPA whose disease became clinically and serologically active during pregnancy is described, representing the first human model supporting the interpretation that MPO-ANCAs were immunopathogenic. Expand
Primary focal segmental glomerulosclerosis: clinical course and response to therapy.
TLDR
The clinical course and response to therapy in patients with primary FSGS is reviewed to better understand the nephrologists' approach to steroid therapy. Expand
...
1
2
3
4
5
...